Business Wire

Estée Lauder Launches Emerging Leaders Fund to Advance the Next Generation of Women Redefining Leadership

Share

Estée Lauder, the flagship brand of The Estée Lauder Companies Inc., is proud to announce the launch of the Estée Lauder Emerging Leaders (ELEL) Fund, a charitable fund under The Estée Lauder Companies Charitable Foundation. The ELEL Fund’s mission is to redefine leadership by supporting a new generation of emerging women leaders and challenging the gender stereotypes of leadership. The Fund will support global organizations that provide opportunities for leadership development, cultivate supportive communities and advocate for emerging leaders who have a daring vision for change.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005425/en/

Estée Lauder has made an initial $1MM investment into the ELEL Fund which will support mission-aligned organizations. Vital Voices, a global nonprofit that invests in women leaders, has been selected as the inaugural program partner of the ELEL Fund, with the program commencing in July 2022. Additional grants by the ELEL Fund will be announced in the coming year.

Global Leadership and Gender Report by Estée Lauder
To gain a deeper understanding of perceptions of leadership and gender bias around the world, the Estée Lauder brand commissioned Glocalities, an international market research agency, for a global study of more than 5,700 men and women across 11 countries. The research revealed that whilst there are still prevalent gender biases and stereotypes when it comes to leadership, both men and women value the same qualities in a leader - reliability, integrity and dedication - which are not attached to gender. However, while leadership qualities such as strength and determination are equally valued by both men and women they are more strongly associated with men. The study reveals the roadblocks and solutions for advancing gender-inclusive leadership.

Estée Lauder’s Legacy
As one of the leading prestige beauty brands in the world, Estée Lauder continues to be inspired by its founder, Mrs. Estée Lauder, and her belief in a woman’s infinite possibilities. The ELEL Fund will reinforce the brand’s commitment to women’s advancement by addressing some of the gender-based biases uncovered in the research and shifting the perception of leadership.

“The 75-year legacy of the Estée Lauder brand shows what one visionary woman can achieve,” said Stéphane de La Faverie, Group President, The Estée Lauder Companies and Global Brand President, Estée Lauder & AERIN Beauty. “Through the work of the Estée Lauder Emerging Leaders Fund and its program partners, we will champion women to contribute and lead in their workplaces and communities. We want to redefine what it means to be a leader and what it takes to lead. We want to see more women like Mrs. Estée Lauder in the world.”

The VV Visionaries Leadership Program in partnership with the ELEL Fund
The Estée Lauder Emerging Leaders Fund selected Vital Voices, a global nonprofit that invests in women leaders who are taking on the world’s greatest challenges, as its first official program partner and grant recipient. With the shared mission of advancing women and redefining leadership, the ELEL Fund and Vital Voices have built a custom online and offline leadership development program for emerging leaders globally. Program participants will join the Vital Voices community of over 20,000 women across 184 countries, which includes Estée Lauder Global Changemaker, Amanda Gorman. Applications are now open for the first and second cohort and can be accessed at www.vitalvoices.org/program/visionaries.

“At Vital Voices we have seen that women lead differently, and that difference is precisely what our world needs,” said Alyse Nelson, Vital Voices President and CEO. “Our partnership with the Estée Lauder Emerging Leaders Fund will identify emerging leaders with a bold vision for positive change and provide them with the skills, network and resources they need to make that vision a reality.”

To learn more about the ELEL Fund, visit esteelauder.com.

Follow @esteelauder and #LeadYourWay hashtag to join the conversation.

About Estée Lauder
Estée Lauder is the flagship brand of The Estée Lauder Companies Inc. Founded by Estée Lauder, one of the world’s first female entrepreneurs, the brand today continues her legacy of creating innovative, sophisticated, high-performance skincare and makeup products and iconic fragrances – all infused with a deep understanding of women’s needs and desires. Today, Estée Lauder engages with customers in more than 150 countries and territories around the world and across dozens of touch points – from in-store to digital. And each of these relationships consistently reflects Estée’s powerful and authentic woman-to-woman point of view. Follow @esteelauder on Instagram, Facebook, Twitter, TikTok and YouTube.

About The Estée Lauder Emerging Leaders Fund
The Estée Lauder Emerging Leaders Fund is a charitable fund of The Estée Lauder Companies Charitable Foundation, a U.S. based charity incorporated and tax exempt in the United States of America.

About Vital Voices
Driven by the universal truth that women are the key to progress in their communities and that nations can’t move forward without women in leadership positions, Vital Voices Global Partnership has directly invested in more than 20,000 changemakers across 184 countries and territories over the last 24 years. It has provided early support for leaders who went on to become Nobel Peace Prize Laureates, U.S. Youth Poet Laureates, Prime Ministers, award-winning innovators, pioneering human rights defenders, and breakthrough social entrepreneurs, including Amanda Gorman, Malala Yousafzai, and more. Serving as a “venture catalyst,” the non-profit identifies leaders with a daring vision for change and partners with them to make that vision a reality. It provides connections, increased capacity, a peer network, financial support, skills training, and increased visibility for their work, which ranges from gender-based violence to the climate crisis, economic inequities. Follow @vitalvoices on Instagram, Facebook, Twitter, LinkedIn, and YouTube.

ELB-B

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contacts

Tara Connaughton, Estée Lauder, tconnaug@estee.com
Stephanie Katz, Estée Lauder, skatz@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye